Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 11, 2007

Hypertension. 2007
Published online before print June 11, 2007, doi: 10.1161/HYPERTENSIONAHA.107.086843
A more recent version of this article appeared on August 1, 2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/2/348    most recent
HYPERTENSIONAHA.107.086843v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muthumala, A.
Right arrow Articles by Humphries, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muthumala, A.
Right arrow Articles by Humphries, S. E.
Related Collections
Right arrow Clinical genetics
Right arrow Other hypertension
Right arrow Acute myocardial infarction
Right arrow Genetics of cardiovascular disease

Submitted on January 12, 2007
Revised on February 1, 2007

Angiotensin-Converting Enzyme Genotype Interacts With Systolic Blood Pressure to Determine Coronary Heart Disease Risk in Healthy Middle-Aged Men

Amal Muthumala*; Hugh Montgomery; Jutta Palmen; Jackie A. Cooper; and Steve E. Humphries

From the Centre For Cardiovascular Genetics (A.M., J.P., J.A.C., S.E.H.), Royal Free and UCL Medical School, The Rayne Institute, London, UK; and the Institute for Human Health and Performance (H.M.), London, UK.

* To whom correspondence should be addressed. E-mail: amal.muthumala{at}uclh.org.

Abstract--The impact of the ACE I/D polymorphism on coronary heart disease (CHD) risk is modest at most, however it may act as a modifier gene. ACE genotype was determined in 2711 healthy middle-aged men (mean age 56 years) followed for 15 years. No genotype-CHD risk association was found, but when analyzed by quartiles of systolic blood pressure (SBP), compared with II homozygotes, carriage of each additional D allele was protective at lower SBP, but in the highest quartile (SBP >150 mm Hg) conferred almost 1.5 times the risk for CHD (genotype interaction P=0.003). When SBP was analyzed as a continuous variable, again a highly significant association was seen, with the hazard ratio ([95% CI]) for a 1 SD increase in SBP being 0.90 [0.70 to 1.15] for IIs and 1.40 [1.21 to 1.61] for ID/DD (genotype SBP interaction P=0.002). The D allele was protective against CHD at lower SBP but would overtake the II risk at higher SBP. In hypertension, the proinflammatory or prohypertrophic properties of angiotensin II may explain this association. The LPL S447X polymorphism also impacts on CHD risk through interaction with hypertension, and there was an additive action of these 2 polymorphisms and SBP on CHD risk (hazard ratio for 1 SD increase in SBP for combined genotypes 1.78 [1.30 to 2.45]). Thus in the presence of hypertension, common variation in "modifier" genes confers significant CHD risk.


Key words: systolic • risk factors • genetics-association studies • ACE gene • CHD • hypertension